denkapparat Operations GmbH Takes $911,000 Position in Johnson & Johnson (NYSE:JNJ)

denkapparat Operations GmbH purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,296 shares of the company's stock, valued at approximately $911,000. Johnson & Johnson comprises 1.3% of denkapparat Operations GmbH's investment portfolio, making the stock its 9th largest holding.

A number of other large investors also recently bought and sold shares of the stock. IFS Advisors LLC lifted its holdings in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after acquiring an additional 100 shares in the last quarter. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $29,000. Bay Harbor Wealth Management LLC acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $32,000. RPg Family Wealth Advisory LLC purchased a new position in Johnson & Johnson in the 3rd quarter worth approximately $35,000. Finally, Runnymede Capital Advisors Inc. purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $38,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the company's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company's stock.

Remove Ads

Johnson & Johnson Stock Performance

Johnson & Johnson stock traded up $1.83 during mid-day trading on Monday, hitting $165.54. 3,311,696 shares of the company's stock traded hands, compared to its average volume of 9,004,041. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99. The company has a market cap of $398.92 billion, a PE ratio of 24.90, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The firm has a 50 day moving average price of $158.68 and a 200 day moving average price of $156.07. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter in the prior year, the company posted $2.29 earnings per share. The company's quarterly revenue was up 5.3% compared to the same quarter last year. On average, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.00%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson's dividend payout ratio is presently 74.59%.

Analyst Ratings Changes

JNJ has been the topic of several analyst reports. Barclays lifted their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a research note on Tuesday, January 28th. Citigroup cut their price target on Johnson & Johnson from $185.00 to $175.00 and set a "buy" rating on the stock in a research note on Wednesday, December 11th. Guggenheim reaffirmed a "neutral" rating on shares of Johnson & Johnson in a research report on Monday, March 10th. Royal Bank of Canada restated an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Finally, Argus upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus target price of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.